Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 51 to 100 of 797

TitleReference numberPublishedLast updated
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Atogepant for preventing migraineTA973
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Dupilumab for treating moderate to severe prurigo nodularisTA955
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930

Results per page

  1. 10
  2. 25
  3. 50
  4. All